Clinical side effects during peripheral blood progenitor cell infusion

Basit Öğe Kaydı
dc.contributor.authorDonmez, Ayhan
dc.contributor.authorTombuloglu, Murat
dc.contributor.authorGungor, Ayse
dc.contributor.authorSoyer, Nur
dc.contributor.authorSaydam, Güray
dc.contributor.authorCagirgan, Seckin
dc.date.accessioned2019-10-27T19:36:41Z
dc.date.available2019-10-27T19:36:41Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractThere are several side effects which have been reported during the infusion of peripheral blood progenitor cells (PBPCs) either due to the infusion or the content of the infusate. We have evaluated the side effects detected during PBPCs infusion in 194 autologous and 25 allogeneic transplantations. In autologous cryopreserved PBPCs infusion, we detected a total of forty-nine (25.25%) side effect events during and after the infusion period. Forty-six (23.71%) of these side effects were detected during the infusion period including fifteen (7.73%) cardiac side effects, which required stopping the infusion, and thirty-one (15.97%) non-cardiac side effects, which did not require cessation of the infusion. Sinus bradycardia after a minimum of 45 min after completing the infusion was seen in three (1.54'%) patients. The median volume, dimethyl sulfoxide (DMSO) and total nucleated cell (TNC) content of the product were found to be significantly higher in patients with side effects compared to the group without any side effects (P < 0.05). The median volume and DMSO content were found to be significantly higher in patients with cardiac side effects compared to non-cardiac side effects (P < 0.05). There was no cardiac side effects in patients treated with an infusate containing 100 x 10(9) L-1 leukocytes. We did not observe any infusion-related side effects in patients given allogeneic non-cryopreserved PBPCs. We have concluded that the volume, DMSO and TNC content of autologous cryopreserved PBPCs product are directly related to clinical side effects. (c) 2006 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.transci.2006.05.019en_US
dc.identifier.endpage101en_US
dc.identifier.issn1473-0502
dc.identifier.issue1en_US
dc.identifier.pmid17236813en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage95en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2006.05.019
dc.identifier.urihttps://hdl.handle.net/11454/39884
dc.identifier.volume36en_US
dc.identifier.wosWOS:000245704500015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPBPCs transplantationen_US
dc.subjectinfusionen_US
dc.subjectside effectsen_US
dc.titleClinical side effects during peripheral blood progenitor cell infusionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu